Samuel C. Blackman - Dec 1, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Medical Officer
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Dec 1, 2022
Transactions value $
-$214,530
Form type
4
Date filed
12/5/2022, 03:43 PM
Previous filing
Nov 17, 2022
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$195K -9.1K -0.72% $21.38 1.26M Dec 1, 2022 Direct F1, F2
transaction DAWN Common Stock Sale -$19.9K -900 -0.07% $22.16 1.26M Dec 1, 2022 Direct F1, F3
holding DAWN Common Stock 1M Dec 1, 2022 By the 2021 Blackman Family LLC F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 to $22.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Reporting Person is the sole manager, and has shared voting and dispositive power with his wife as members. The Reporting Person continues to report beneficial ownership of all of the Issuer's Common Stock held by the 2021 Blackman Family LLC but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest therein.